Market Intelligence, Clinical Progress, and High-Purity Reagents for Complement-Mediated Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CFB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CFB Full-length / Bb Fragment Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CFB Products |
| Gene Delivery | CFB Promise-ORF / Lentivirus Full-length ORF for stable overexpression cell lines. |
View CFB Products |
| Benchmark Ab | Anti-CFB (Reference Biosimilar / Clinical Benchmark Sequence) Recombinant positive control for binding assays. |
View CFB Products |
| Validator | CFB siRNA Set For knockdown verification in cell-based assays. |
View CFB Products |
| Related Target: C3 | Complement C3 Substrate for CFB protease activity; downstream convergence point. |
View C3 Products |
| Related Target: Factor D (CFD) | Complement Factor D Upstream activator protease that cleaves CFB; synergistic inhibition strategy. |
View CFD Products |
| Related Target: C5 | Complement C5 Terminal complement pathway component for comparative efficacy. |
View C5 Products |
Critical Assay Challenges & Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protease Activity Validation & Structural Integrity | Sequence-verified CFB Bb fragment with confirmed serine protease domain activity; HEK293 expression ensures correct folding and native glycosylation. High purity (>95%) ensures low background. |
| Cross-species Evaluation (Cyno/Mouse) | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity for accurate PK/PD bridging. |
| Factor D vs CFB Selectivity Screening | Homolog panel (CFB, Factor D, C2) proteins strictly verified by mass spec; eliminate off-target serine protease inhibition. |
| C3 Convertase Assembly (C3bBb) | Native folded CFB protein with properdin cofactor binding capacity; supports complex formation assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives (Endotoxin) | Endotoxin strictly controlled (<1EU/ug) to prevent non-specific complement activation; validated siRNA included for cellular assay specificity checks. |
Key Molecular Features
Based on UniProt P00751:
- Functional Domains: CFB contains three Sushi (CCP) domains — Sushi 1, Sushi 2, and Sushi 3 — critical for C3b binding and properdin interaction.
- Key Genetic Variants:
- R32W (rs4151667): may be associated with a reduced risk for age-related macular degeneration.
- D279E (in allele FA; requires two nucleotide substitutions).
- G252S (in allele S).
Global Clinical Landscape & Future Outlook
The race for Complement Factor B (CFB) therapeutics is intensifying, with major players shifting focus from terminal complement inhibitors (like C5 mAbs) to upstream Alternative Pathway (AP) regulation. As first-generation small molecule inhibitors achieve regulatory milestones for rare blood disorders, the next wave of R&D is targeting chronic, high-burden indications such as IgA nephropathy, C3 glomerulopathy, and geographic atrophy. The dominant modalities are expanding from oral small molecules to long-acting antisense oligonucleotides (ASOs) and siRNA.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Novartis | PNH, IgAN, C3G, aHUS | Selectivity Assay (Need High-Purity active CFB proteins) |
| ASO / siRNA | Ionis, Alnylam, Novartis | Geographic Atrophy, IgAN | In vitro Knockdown Validation (Need Sequence-Verified siRNA & Cell Lines) |
| Monoclonal Antibody | Various Biotechs | Alternative Pathway Overactivation | Affinity Kinetics (Need Endotoxin-controlled, HEK293 expressed antigens) |
Live CFB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: